Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo

American Journal of Pathology

Volumn 167, Issue 5, 2005, Pages 1341-1348

  Henriksen, Kim ^a,e   Gram, Jeppe ^b   Høegh Andersen, Pernille ^a   Jemtland, Rune ^d   Ueland, Thor ^d   Dziegiel, Morten H ^c   Schaller, Sophie ^a   Bollerslev, Jens ^d   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e Pharmos Bioscience A/S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN K; CD14 ANTIGEN; CELL PROTEIN; CLC7 PROTEIN; COLONY STIMULATING FACTOR 1; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ADULT; ALBERS SCHOENBERG DISEASE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT OSTEOPETROSIS TYPE I; BONE MASS; BONE MINERALIZATION; CELL COUNT; CELL ISOLATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LRP5 GENE; MALE; MONOCYTE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 27544493733     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61221-7     Document Type: Article

References (44)

1. Bollerslev J: Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. Endocr Rev 1989, 10:45-67
2. Bollerslev J, Marks Jr SC, Pockwinse S, Kassem M, Brixen K, Steiniche T, Mosekilde L: Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 1993, 14:865-869
3. Bollerslev J, Thomas S, Grodum E, Brixen K, Djoseland O: Collagen metabolism in two types of autosomal dominant osteopetrosis during stimulation with thyroid hormones. Eur J Endocrinol 1995, 133:557-563
4. Bollerslev J, Ueland T, Grodum E, Haug E, Brixen K, Djoseland O: Biochemical markers of bone metabolism in benign human osteopetrosis: a study of two types at baseline and during stimulation with triiodothyronine. Eur J Endocrinol 1998, 139:29-35
5. Bollerslev J, Steiniche T, Melsen F, Mosekilde L: Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. Bone 1989, 10:19-24
6. Bollerslev J, Nielsen HK, Larsen HF, Mosekilde L: Biochemical evidence of disturbed bone metabolism and calcium homeostasis in two types of autosomal dominant osteopetrosis. Acta Med Scand 1988, 224:479-483
7. Brockstedt H, Bollerslev J, Melsen F, Mosekilde L: Cortical bone remodeling in autosomal dominant osteopetrosis: a study of two different phenotypes. Bone 1996, 18:67-72
8. Van Hul E, Gram J, Bollerslev J, van Wesenbeeck L, Mathysen D, Andersen PE, Vanhoenacker F, Van Hul W: Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. J Bone Miner Res 2002, 17:1111-1117
9. van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, de Vernejoul MC, Bollerslev J, Van Hul W: Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72:763-771
10. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP: High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-1521
11. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML: A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70:11-19
12. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523
13. Koay MA, Woon PY, Zhang Y, Miles LJ, Duncan EL, Ralston SH, Compston JE, Cooper C, Keen R, Langdahl BL, MacLelland A, O'Riordan J, Pols HA, Reid DM, Uitterlinden AG, Wass JA, Brown MA: Influence of LRP5 polymorphisms on normal variation in BMD. J Bone Miner Res 2004, 19:1619-1627
14. Mizuguchi T, Furuta I, Watanabe Y, Tsukamoto K, Tomita H, Tsujihata M, Ohta T, Kishino T, Matsumoto N, Minakami H, Niikawa N, Yoshiura K: LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density. J Hum Genet 2004, 49:80-86
15. Bollerslev J, Wilson SG, Dick IM, Islam FMA, Ueland T, Palmer L, Devine A, Prince RL: LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women. Bone 2005, 36:599-606
16. Koller DL, Ichikawa S, Johnson ML, Lai D, Xuei X, Edenberg HJ, Conneally PM, Hui SL, Johnston CC, Peacock M, Foroud T, Econs MJ: Contribution of the LRP5 gene to normal variation in peak BMD in women. J Bone Miner Res 2005, 20:75-80
17. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L: Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002, 157:303-314
18. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO: Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 2004, 19:2033-2040
19. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F: High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003, 18:960-974
20. Gram J, Antonsen S, Horder M, Bollerslev J: Elevated serum levels of creatine kinase BB in autosomal dominant osteopetrosis type II. Calcif Tissue Int 1991, 48:438-439
21. Bollerslev J, Ueland T, Landaas S, Marks Jr SC: Serum creatine kinase isoenzyme BB in mammalian osteopetrosis. Clin Orthop 2000, 377:241-247
22. Van Hul E, Gram J, Bollerslev J, van Wesenbeeck L, Mathysen D, Andersen PE, Vanhoenacker F, Van Hul W: Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. J Bone Miner Res 2002, 17:1111-1117
23. van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, de Vernejoul MC, Bollerslev J, Van Hul W: Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72:763-771
24. Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J, Karsdal MA: Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 2004, 164:1537-1545
25. Henriksen K, Karsdal M, Delaisse JM, Engsig MT: RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 2003, 278:48745-48753
26. Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaisse JM, Foged NT: TGF-beta controls human osteoclastogenesis through the p38 MAP kinase and regulation of RANK expression. J Biol Chem 2003, 278:44975-44987
27. Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J: Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 2005, 166:467-476
28. Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, Redini F: Regulation of osteoclast protease expression by RANKL. Biochem Biophys Res Commun 2003, 310:774-778
29. Roodman GD: Cell biology of the osteoclast. Exp Hematol 1999, 27:1229-1241
30. Littlewood-Evans A, Kokubo T, Ishibashi O, Inaoka T, Wlodarski B, Gallagher JA, Bilbe G: Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 1997, 20:81-86
31. Kamiya T, Kobayashi Y, Kanaoka K, Nakashima T, Kato Y, Mizuno A, Sakai H: Fluorescence microscopic demonstration of cathepsin K activity as the major lysosomal cysteine proteinase in osteoclasts. J Biochem (Tokyo) 1998, 123:752-759
32. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ: Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001, 104:205-215
33. Oshiro T, Shibasaki Y, Martin TJ, Sasaki T: Immunolocalization of vacuolar-type H+-ATPase, cathepsin K, matrix metalloproteinase-9, and receptor activator of NFkappaB ligand in odontoclasts during physiological root resorption of human deciduous teeth. Anat Rec 2001, 264:305-311
34. Sasaki T: Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. Microsc Res Tech 2003, 61:483-495
35. Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Helix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiodt CB, Sorensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaisse JM, Engsig MT, Karsdal MA: The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004, 19:1144-1153
36. Vaaraniemi J, Halleen JM, Kaarlonen K, Ylipahkala H, Alatalo SL, Andersson G, Kaija H, Vihko P, Vaananen HK: Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res 2004, 19:1432-1440
37. Bollerslev J, Ueland T, Odgren PR: Serum levels of TGF-beta and fibronectin in autosomal dominant osteopetrosis in relation to underlying mutations and well-described murine counterparts. Crit Rev Eukaryot Gene Expr 2003, 13:163-171
38. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764
39. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319
40. Day TF, Guo X, Garrett-Beal L, Yang Y: Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8:739-750
41. Zhang Y, Wang Y, Li X, Zhang J, Mao J, Li Z, Zheng J, Li L, Harris S, Wu D: The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol 2004, 24:4677-4684
42. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF: Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996, 2:1132-1136
43. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268
44. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ: Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448